EXEL · Exelixis
27 filings
EXEL 10-K Annual Reports
Exelixis - 27 annual reports
EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.
- 8-K · Feb 16, 2016
- 10-K · Feb 29, 2016
- 8-K · Feb 29, 2016
- 10-Q · May 4, 2016
- 8-K · May 4, 2016
- 8-K · May 26, 2016
- 10-Q · Aug 3, 2016
- 8-K · Aug 3, 2016
- 8-K · Aug 9, 2016
- 8-K · Aug 22, 2016
- 8-K · Sep 26, 2016
- 10-Q/A · Sep 30, 2016
- 8-K · Nov 3, 2016
- 10-Q · Nov 3, 2016
- 8-K · Nov 22, 2016
- 8-K · Dec 21, 2016
- 8-K · Jan 31, 2017
- 8-K · Feb 27, 2017
- 10-K · Feb 27, 2017
- 10-Q · May 1, 2017
- 8-K · May 1, 2017
- 8-K · May 2, 2017
- 8-K · May 11, 2017
- 8-K · May 25, 2017
- 10-Q/A · Jul 14, 2017
- 8-K · Jul 20, 2017
- 8-K · Aug 2, 2017
- 10-Q · Aug 2, 2017
- 8-K/A · Sep 8, 2017
- 8-K · Sep 8, 2017
- 8-K · Nov 1, 2017
- 10-Q · Nov 1, 2017
- 8-K · Feb 16, 2018
- 10-K · Feb 26, 2018
- 8-K · Feb 26, 2018
- 8-K · Apr 9, 2018
- 8-K · May 2, 2018
- 10-Q · May 2, 2018
- 8-K · May 24, 2018
- 10-Q · Aug 1, 2018
- 8-K · Aug 1, 2018
- 10-Q · Nov 1, 2018
- 8-K · Nov 1, 2018
- 8-K · Feb 12, 2019
- 8-K · Feb 21, 2019
- 10-K · Feb 22, 2019
- 8-K · Mar 5, 2019
- 8-K · Apr 5, 2019
- 8-K · Apr 25, 2019
- 8-K · May 1, 2019
- 10-Q · May 1, 2019
- 8-K · May 23, 2019
- 8-K · Jun 20, 2019
- 10-Q · Jul 31, 2019
- 8-K · Jul 31, 2019
- 8-K · Sep 26, 2019
- 8-K · Oct 7, 2019
- 10-Q · Oct 30, 2019
- 8-K · Oct 30, 2019
- 8-K · Dec 19, 2019
- 8-K · Jan 13, 2020
- 8-K · Feb 20, 2020
- 10-K · Feb 25, 2020
- 8-K · Feb 25, 2020
- 8-K · Mar 2, 2020
- 8-K · Apr 20, 2020
- 8-K · May 5, 2020
- 10-Q · May 5, 2020
- 8-K · May 12, 2020
- 8-K · May 22, 2020
- 8-K · Aug 6, 2020
- 10-Q · Aug 6, 2020
- 8-K · Nov 5, 2020
- 10-Q · Nov 5, 2020
- 8-K · Jan 11, 2021
- 8-K · Feb 5, 2021
- 8-K · Feb 10, 2021
- 10-K · Feb 11, 2021
- 8-K · Mar 3, 2021
- 8-K · Mar 5, 2021
- 10-Q · May 6, 2021
- 8-K · May 6, 2021
- 8-K · May 11, 2021
- 8-K · May 27, 2021
- 8-K · Jun 21, 2021
- 8-K · Jun 21, 2021
- 8-K · Aug 5, 2021
- 10-Q · Aug 5, 2021
- 8-K · Nov 2, 2021
- 10-Q · Nov 2, 2021
- 8-K · Dec 17, 2021
- 8-K · Jan 10, 2022
- 8-K · Feb 17, 2022
- 10-K · Feb 18, 2022
- 8-K · Feb 23, 2022
- 8-K · Apr 13, 2022
- 10-Q · May 10, 2022
- 8-K · May 10, 2022
- 8-K · May 27, 2022
- 8-K · Jul 19, 2022
- 8-K · Aug 9, 2022
- 10-Q · Aug 9, 2022
- 8-K · Sep 2, 2022
- 10-Q · Nov 1, 2022
- 8-K · Nov 1, 2022
- 8-K · Dec 15, 2022
- 8-K · Jan 9, 2023
- 10-K · Feb 7, 2023
- 8-K · Feb 7, 2023
- 8-K · Mar 20, 2023
- 8-K · Mar 22, 2023
- 8-K · Apr 13, 2023
- 8-K · May 8, 2023
- 10-Q · May 9, 2023
- 8-K · May 9, 2023
- 8-K · Jun 5, 2023
- 8-K · Jul 24, 2023
- 8-K · Aug 1, 2023
- 10-Q · Aug 1, 2023
- 8-K · Aug 23, 2023
- 8-K · Sep 19, 2023
- 10-Q · Nov 1, 2023
- 8-K · Nov 1, 2023
- 8-K · Dec 20, 2023
- 8-K · Jan 8, 2024
- 10-K · Feb 6, 2024
- 8-K · Feb 6, 2024
- 8-K · Mar 29, 2024
- 8-K · Apr 30, 2024
- 10-Q · Apr 30, 2024
- 8-K · May 10, 2024
- 8-K · May 20, 2024
- 8-K · Jun 3, 2024
- 8-K · Aug 6, 2024
- 10-Q · Aug 6, 2024
- 8-K · Oct 15, 2024
- 8-K · Oct 15, 2024
- 10-Q · Oct 29, 2024
- 8-K · Oct 29, 2024
- 8-K · Jan 13, 2025
- 8-K · Feb 11, 2025
- 10-K · Feb 11, 2025
- 8-K · Feb 21, 2025
- 8-K · Mar 31, 2025
- 10-Q · May 13, 2025
- 8-K · May 13, 2025
- 8-K · Jun 2, 2025
- 8-K · Jul 28, 2025
- 10-Q · Jul 28, 2025
- 8-K · Aug 29, 2025
- 10-Q · Nov 4, 2025
- 8-K · Nov 4, 2025
- 8-K · Nov 7, 2025
- 8-K · Jan 12, 2026
- 8-K · Feb 10, 2026
- 10-K · Feb 10, 2026
- 10-Q · May 5, 2026
- 8-K · May 5, 2026
- 8-K · May 29, 2026
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026
- 8-K · Aug 31, 2026
- 8-K · Sep 11, 2026
- 8-K · Oct 29, 2026
- 10-Q · Oct 29, 2026
- 2026Feb 10, 2026
Exelixis Annual Report, Year Ended Jan 2, 2026
Exelixis, Inc. (Exelixis, we, our or us) reported 2025 as its ninth consecutive year of annual profitability, with total revenues of $2,320.1 million, up from $2,168.7 million in 2024, and net income of $782.6 million, or $2.78 per diluted share, compared with $521.3 million, or $1.76 per diluted share, in 2024. Net product revenues rose to $2,122.8 million, driven by CABOMETYX, which generated $2,113.4 million, with the filing citing a 16% increase in CABOMETYX units sold, largely from first-line RCC use with nivolumab and previously treated advanced NET. Collaboration revenues fell to $197.3 million from $359.3 million, reflecting lower license revenue from the absence of the large 2024 Ipsen sales milestone. The company ended 2025 with $1.66 billion in cash, cash equivalents and marketable securities, versus $1.75 billion a year earlier, after returning cash through share repurchases. It repurchased 30.2 million shares for $1,159.7 million under its repurchase programs, and $590.2 million remained available under the October 2025 program, which runs through December 31, 2026. Operating cash flow was $884.3 million. Research and development expense declined to $825.0 million from $910.4 million, while management projects R&D expense may increase in 2026 due to zanzalintinib, XB628, XB371 and XB010 trials. The main forward-looking catalysts are zanzalintinib, for which an NDA with atezolizumab in previously treated metastatic colorectal cancer was accepted with a PDUFA target action date of December 3, 2026, and STELLAR-304 top-line results expected in mid-2026. Investors face material risks from generic cabozantinib competition: multiple ANDA and 505(b)(2) filers have Paragraph IV challenges to CABOMETYX patents, with a consolidated trial scheduled for November 2, 2026, and the composition-of-matter patent with term extension expires in August 2026. The company also faces U.S. drug pricing policy and 340B Program litigation risks.
- 2025Feb 11, 2025
Exelixis Annual Report, Year Ended Jan 3, 2025
Exelixis, Inc. reported its eighth consecutive year of annual profitability for 2024, with net income of $521.3 million, or $1.76 per diluted share, compared with $207.8 million, or $0.65 per share, in 2023. Total revenues rose to $2,168.7 million from $1,830.2 million, driven by net product revenues of $1,809.4 million, almost entirely from CABOMETYX, and license revenues of $349.2 million, which include a $150.0 million commercial milestone from Ipsen. Fiscal 2024 was a 53-week year. The company ended the year with $1.7 billion in cash, cash equivalents and marketable securities and repurchased $652.0 million of its common stock during 2024 under two programs. The company's growth depends on CABOMETYX, which the filing says accounts for the majority of revenues. The filing notes that the CABOMETYX plus nivolumab first-line RCC combination drove the 8.2% increase in CABOMETYX units sold. Pipeline catalysts include the pending FDA decision on CABINET (pNET/epNET) with a PDUFA date of April 3, 2025, and the lead investigational asset zanzalintinib, with several pivotal trials ongoing. The company also reported that COSMIC-313 did not show an overall survival benefit and will not be pursued for marketing authorization. CONTACT-02 showed a non-significant overall survival trend. The filing also flags material risks. Generic challengers have filed ANDAs against CABOMETYX: MSN, Teva, Cipla and Sun. Settlements with Teva and Cipla allow generic entry beginning January 1, 2031, and a court judgment sets MSN's earliest effective approval date at January 15, 2030. The 340B Program Integrity Initiative is under challenge, and the IRA drug-pricing provisions create additional uncertainty. Management projects higher 2025 net product revenues, lower license revenues and higher R&D expense.
- 2023Feb 6, 2024
Exelixis Annual Report, Year Ended Dec 29, 2023
Exelixis, Inc. reported its seventh consecutive year of annual profitability in 2023, with net income of $207.8 million ($0.65 per share, basic and diluted), compared with $182.3 million in 2022. Total revenues were $1,830.2 million versus $1,611.1 million, and net product revenues were $1,628.9 million, up 16% year over year. CABOMETYX drove the result, with net product revenues of $1,614.9 million, and the filing attributes the growth to a 9% increase in units sold following the FDA approval of CABOMETYX in combination with nivolumab for first-line advanced RCC, plus a 7% increase in average net selling price. Royalties earned on ex-U.S. cabozantinib sales were $148.5 million, up from $121.4 million. Operating expenses rose, with research and development expenses of $1,044.1 million (versus $891.8 million) and selling, general and administrative expenses of $542.7 million (versus $459.9 million). Interest income more than doubled to $86.5 million. Cash, cash equivalents and investments totaled $1.7 billion at year-end, down from $2.1 billion, mainly because the company repurchased $550.4 million of common stock during 2023. In January 2024 the Board authorized a further repurchase of up to $450.0 million and the company announced a restructuring that reduces its workforce by about 175 employees, or 13% of headcount, and terminates several research collaborations. The pipeline's key near-term events include the CONTACT-02 phase 3 trial in mCRPC, which met one of two primary endpoints (PFS), with overall survival still pending; the CABINET phase 3 trial in neuroendocrine tumors, where the company is discussing a potential FDA submission in 2024; and the zanzalintinib program, now in phase 3 trials. Investors should also note the risk from generic competition: ANDAs from MSN, Teva and Cipla challenge CABOMETYX patents, and the company settled with Teva in July 2023 on a license effective January 1, 2031. The MSN II bench trial occurred in October 2023 with judgment expected in the first half of 2024.
- 2022Feb 7, 2023
Exelixis Annual Report, Year Ended Dec 30, 2022
Exelixis, Inc. reported its sixth consecutive year of annual profitability for 2022, with net income of $182.3 million, or $0.56 per diluted share, compared with $231.1 million in 2021. Total revenues were $1,611.1 million, up from $1,434.97 million in 2021, driven by net product revenues of $1,401.2 million (CABOMETYX $1,375.9 million and COMETRIQ $25.3 million). Royalties earned outside the U.S. on cabozantinib sales were $121.4 million in 2022. Operating expenses rose, with research and development at $891.8 million and selling, general and administrative at $459.9 million, reflecting ongoing investment in late-stage trials and the pipeline. The company held $2.1 billion in cash, cash equivalents, restricted cash equivalents and investments at year-end, and management states this should support operations for at least 12 months. The company's near-term outlook depends heavily on CABOMETYX. Management projects higher net product revenues in 2023, while also expecting license revenues and collaboration services revenues to decline and research and development and selling, general and administrative expenses to increase. Key pipeline catalysts include CONTACT-03 and CONTACT-02 primary PFS readouts in 2023, the next OS analysis of COSMIC-313, and the zanzalintinib phase 3 programs STELLAR-303 and STELLAR-304. The COSMIC-313 triplet regimen met its PFS endpoint but did not show a significant OS benefit at a prespecified interim analysis, and the company does not intend to file an sNDA on current data. CONTACT-01 did not meet its primary OS endpoint. The filing also highlights significant generic-entry risk. Paragraph IV notices from MSN, Teva and Cipla challenge patents covering CABOMETYX. In January 2023, the Delaware District Court ruled in the MSN I case that MSN's ANDA product does not infringe U.S. Patent No. 8,877,776 and set the effective approval date no earlier than August 14, 2026. The MSN II bench trial is scheduled for October 2023. Investors should weigh strong 2022 growth and profitability against this patent exposure and the company's high spending on discovery and clinical development.
- 2021Feb 18, 2022
Exelixis Annual Report, Year Ended Dec 31, 2021
Exelixis, Inc. (Exelixis) reported its fifth consecutive year of profitability for 2021, with net income of $231.1 million ($0.72 per diluted share) compared with $111.8 million in 2020, and total revenues of $1,435.0 million, up from $987.5 million. Net product revenues were $1,077.3 million, driven mainly by CABOMETYX (cabozantinib), which generated $1,054.1 million, a 42% increase in units sold that the filing attributes largely to uptake of the CABOMETYX plus OPDIVO first-line RCC combination approved by the FDA in January 2021. Cash and investments rose to $1.9 billion at December 31, 2021, from $1.5 billion a year earlier. The company's near-term value depends heavily on CABOMETYX. The filing flags generic competition: MSN and Teva have filed ANDAs seeking to market generic versions, and Exelixis has sued both. A bench trial against MSN is scheduled for May 2022, and the Teva case has been stayed. The filing states that approval of either ANDA could significantly decrease U.S. CABOMETYX revenues. Royalty income from partners Ipsen and Takeda also grew, and the company expects license revenues to decline in 2022 because fewer milestones are anticipated. Pipeline catalysts for 2022 include top-line COSMIC-313 results in the first half, the final overall survival analysis of COSMIC-312 in the first quarter (the company intends to file an sNDA if supported), interim OS results from CONTACT-01 in the second half, and the planned start of Phase 3 STELLAR-303 for XL092. Management projects higher R&D and SG&A spending and higher 2022 net product revenues.
- 2021Feb 11, 2021
Exelixis Annual Report, Year Ended Jan 1, 2021
Exelixis, Inc. reported total revenues of $987.5 million for fiscal 2020, up from $967.8 million in 2019, and net income of $111.8 million, or $0.35 per diluted share, compared with $321.0 million, or $1.02 per diluted share, in 2019. Net product revenues from CABOMETYX and COMETRIQ declined to $741.6 million from $760.0 million, which the company attributes in part to COVID-19 reducing prescriptions. Growth in total revenue came from license revenues of $167.3 million and collaboration services revenues of $78.7 million, which rose from $41.9 million. Research and development expenses rose to $547.9 million from $337.0 million, and selling, general and administrative expenses rose to $293.4 million from $228.2 million, reflecting expanded clinical trials and business development. Cash and investments totaled $1.54 billion at year-end. The company's near-term growth depends on CABOMETYX, which the FDA approved in combination with OPDIVO as a first-line treatment for advanced renal cell carcinoma on January 22, 2021. Exelixis also reported positive phase 3 results for COSMIC-311 in differentiated thyroid cancer, with a hazard ratio of 0.22, and disclosed that the EXAMINER trial did not meet its primary endpoint. The company is defending patent infringement lawsuits against MSN Pharmaceuticals over a generic version of CABOMETYX, with a bench trial scheduled for May 2022. The filing states the company expects net product revenues to increase in 2021 and license revenues to decrease, and it projects research and development and selling, general and administrative expenses to continue rising. The filing describes a broad oncology pipeline of more than 100 ongoing or planned cabozantinib trials, along with early-stage programs XL092 and XL102 and several research collaborations for antibody-drug conjugates. Revenue concentration is significant: Ipsen accounted for 15% of total revenues in 2020, and three pharmacy and distribution affiliates accounted for 11% to 14% each. Investors should weigh the company's reliance on a single franchise, its exposure to generic competition, and the timing of milestone-driven revenue.
- 2020Feb 25, 2020
Exelixis Annual Report, Year Ended Jan 3, 2020
Exelixis, Inc. (Nasdaq: EXEL) is an oncology-focused biotechnology company whose 2019 results were driven by its flagship molecule cabozantinib, marketed as CABOMETYX (advanced renal cell carcinoma and previously treated hepatocellular carcinoma) and COMETRIQ (progressive, metastatic medullary thyroid cancer). Net product revenues rose to $759.95 million in 2019 from $619.28 million in 2018, with CABOMETYX contributing $733.42 million. Total revenues were $967.78 million, up from $853.83 million, while collaboration revenues declined to $207.83 million from $234.55 million. Net income was $321.01 million, or $1.02 per diluted share, compared with $690.07 million in 2018, which had included a $244.1 million income tax benefit from the release of most of the valuation allowance on deferred tax assets. Cash and investments totaled $1.39 billion at year-end. The company expects 2020 net product revenues to remain in line with 2019 and collaboration revenues to decrease as fewer milestones are expected, while research and development and selling, general and administrative expenses are expected to keep increasing. Research and development expenses rose to $336.96 million from $182.26 million, driven by clinical trial costs and collaboration costs. Key pipeline items include COSMIC-311 (differentiated thyroid cancer), COSMIC-313 and COSMIC-312 phase 3 trials, and XL092, a next-generation oral TKI in phase 1. The filing also discloses a Paragraph IV patent challenge from MSN Pharmaceuticals over a generic CABOMETYX tablet, with Exelixis suing in October 2019; a bench trial is tentatively scheduled for April 2022. Investors should note the concentration of revenue in cabozantinib, reliance on partners Ipsen and Takeda for ex-U.S. commercialization, the generic litigation risk tied to the composition-of-matter patent expiring in 2026, and the lumpy nature of milestone revenue, which was $96.2 million in 2019 versus $164.4 million in 2018.
- 2018Feb 22, 2019
Exelixis Annual Report, Year Ended Dec 28, 2018
Exelixis, Inc. (filed under the name Exelixis, Inc.) is an oncology-focused biotechnology company whose 2018 results were driven by its flagship molecule cabozantinib, marketed as CABOMETYX for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC), and as COMETRIQ for medullary thyroid cancer. For 2018, total revenues were $853.8 million, up from $452.5 million in 2017, and net product revenues were $619.3 million, up from $349.0 million. Net income was $690.1 million, or $2.21 per diluted share, compared with $154.2 million, or $0.49 per diluted share, in 2017. The filing states that the result includes a $244.1 million income tax benefit from the release of substantially all of the valuation allowance against deferred tax assets, and that from 2019 the company expects to record income tax expense at an estimated effective rate between 21% and 23%. The company ended 2018 with $851.6 million in cash and investments, up from $457.2 million a year earlier, and states that it expects its current cash, short-term investments and revenues to fund operations for at least 12 months after the filing date. Its partner-driven revenue base includes Ipsen (outside the U.S. and Japan), Takeda (Japan), and Genentech (cobimetinib, marketed as COTELLIC). The company also reports an FDA approval of CABOMETYX for previously treated HCC on January 14, 2019, supported by the phase 3 CELESTIAL trial, and a broad development program of over 75 ongoing or planned cabozantinib trials, including phase 3 studies COSMIC-311, COSMIC-312 and CheckMate 9ER. The filing highlights key risks: dependence on CABOMETYX's commercial success, intense competition from immune checkpoint inhibitors and other TKIs, reliance on collaboration partners, pricing and reimbursement pressure, and patent exposure, including generic entry risk. The company's composition-of-matter patent for cabozantinib is listed with expiration in 2026 following a patent term extension.
- 2017Feb 26, 2018
Exelixis Annual Report, Year Ended Dec 29, 2017
Exelixis, Inc. reported a return to profitability in 2017, with net income of $154.2 million compared with a net loss of $70.2 million in 2016. Total revenues rose to $452.5 million from $191.5 million, driven by net product revenues of $349.0 million (up from $135.4 million), led by CABOMETYX at $324.0 million, and collaboration revenues of $103.5 million. The company retired all of its outstanding debt during 2017, including the $80.0 million Silicon Valley Bank term loan and the Deerfield Notes for a payment of $123.8 million, leaving no debt on the balance sheet at December 31, 2017. Cash and investments were $457.2 million at year-end, of which $452.0 million was available for operations. The filing states that the company's near-term prospects depend heavily on the commercial success of CABOMETYX in advanced renal cell carcinoma. On December 19, 2017, the FDA approved CABOMETYX for previously untreated advanced RCC, and the company plans to submit a supplemental New Drug Application for previously treated advanced hepatocellular carcinoma in the first quarter of 2018 following positive CELESTIAL trial results. Cobimetinib (COTELLIC) is marketed with Genentech, and the company resolved its arbitration with Genentech in July 2017 through an amended, more favorable revenue and cost-sharing arrangement. Management expects research and development and selling, general and administrative expenses to increase in 2018, and notes that adoption of ASU 2014-09 will reduce accumulated deficit by approximately $260 million for collaboration agreements with Ipsen and Takeda. The filing also flags material risks, including competition from immunotherapies such as nivolumab, pricing and reimbursement pressure, possible generic competition for cabozantinib (the FDA published draft bioequivalence guidance in February 2018), dependence on collaboration partners, and a planned relocation of corporate headquarters to Alameda, California in 2018. The company reported 372 full-time equivalent employees as of December 31, 2017.
- 2016Feb 27, 2017
Exelixis Annual Report, Year Ended Dec 30, 2016
Exelixis, Inc. ("Exelixis") reported total revenues of $191.5 million for 2016, up from $37.2 million in 2015, driven by the April 2016 U.S. launch of CABOMETYX for previously treated advanced renal cell carcinoma (RCC) and by collaboration revenue from its Ipsen agreement. Net product revenues were $135.4 million, including $93.5 million from CABOMETYX and $41.9 million from COMETRIQ. Net loss narrowed to $70.2 million from $161.7 million in 2015, and the company reported a $2.0 billion accumulated deficit. Cash and investments rose to $479.6 million at December 31, 2016, from $253.3 million a year earlier, after the Ipsen upfront and milestone payments and the retirement of the 4.25% 2019 Notes through exchanges and redemption. The company's near-term value depends on expanding cabozantinib. Management plans to submit a supplemental NDA in 2017 for first-line advanced RCC based on the CABOSUN phase 2 trial, and top-line results from the phase 3 CELESTIAL trial in hepatocellular carcinoma are anticipated in 2017. In January 2017 Exelixis signed a Takeda collaboration for Japan, with a $50.0 million upfront payment received in February 2017, and in February 2017 it entered into clinical collaborations with Bristol-Myers Squibb and Roche. Cotellic, marketed by Genentech, is a second potential revenue source, but Exelixis is in arbitration with Genentech over cost and revenue allocations. The balance sheet carries $189.1 million of debt at year-end, including the Deerfield Notes, which management intends to repay on or about July 1, 2017, and an $80.0 million Silicon Valley Bank term loan due May 31, 2017. Deferred revenue of $256.8 million from the Ipsen agreement is a significant liability that will be recognized over the life of the collaboration.
- 2016Feb 29, 2016
Exelixis Annual Report, Year Ended Jan 1, 2016
Exelixis, Inc. ("Exelixis") is a biopharmaceutical company focused predominantly on cabozantinib, a multi-receptor tyrosine kinase inhibitor. Cabozantinib is approved in the United States and European Union for progressive, metastatic medullary thyroid cancer (MTC) under the brand name COMETRIQ, which generated $74.3 million in net revenues from commercial launch through December 31, 2015. Total 2015 revenues were $37.2 million, versus a net loss of $169.7 million, and the accumulated deficit reached $1.9 billion. Cash and investments were $253.3 million at December 31, 2015, of which $169.0 million was available for operations, and the company states that current resources should fund operations for at least 12 months following the filing date. The key near-term catalysts are the NDA for cabozantinib in advanced renal cell carcinoma (RCC), which was granted priority review with a PDUFA action date of June 22, 2016, and the EMA marketing authorization application, which was accepted with accelerated assessment. The METEOR trial showed a 7.4-month median PFS versus 3.8 months for everolimus, and a second interim analysis showed a highly statistically significant overall survival increase. On February 29, 2016, Exelixis entered a collaboration with Ipsen for ex-U.S., Canada and Japan rights, providing a $200.0 million upfront payment, with additional regulatory and commercial milestones and tiered royalties. The company carries significant leverage: total consolidated indebtedness through maturity was $492.5 million, including the 4.25% 2019 Notes ($287.5 million principal), Deerfield Notes ($103.8 million outstanding principal), and a $80.0 million Silicon Valley Bank term loan. Investors should weigh the RCC approval and Ipsen payment against continued net losses, debt maturities beginning in 2017, and dependence on partners such as Genentech for cobimetinib (marketed as COTELLIC).
- 2014Mar 2, 2015
Exelixis Annual Report, Year Ended Dec 31, 2014
Exelixis, Inc. ("Exelixis") is a biopharmaceutical company developing small molecule cancer therapies. Its focus is cabozantinib, which is approved in the U.S. and EU for progressive, metastatic medullary thyroid cancer under the brand name COMETRIQ. COMETRIQ generated net product revenues of $25.1 million in 2014, and the company reported $40.1 million in net revenues from COMETRIQ since its January 2013 launch. Cabozantinib's phase 3 trials in metastatic castration-resistant prostate cancer (COMET-1 and COMET-2) did not meet their primary endpoints, and development in that indication has been terminated. The remaining key pipeline programs are two ongoing phase 3 trials, METEOR in metastatic renal cell carcinoma (top-line data expected in Q2 2015) and CELESTIAL in advanced hepatocellular carcinoma (results expected in 2017). Partner Genentech has an NDA for cobimetinib with priority review and a PDUFA date of August 11, 2015. Financially, the company reported a net loss of $268.5 million for 2014, up from $244.8 million in 2013, and an accumulated deficit of $1.8 billion. Total cash and investments were $242.8 million at year-end, of which $144.3 million was available for operations. Stockholders' deficit was $(114.8) million. Total debt was $361.7 million, including $287.5 million of 4.25% convertible notes due 2019 and $104.0 million of Deerfield Notes due July 1, 2015 unless extended. The company states it expects to maintain operations through at least December 31, 2015, and that its ability to sustain operations beyond that is highly dependent on COMETRIQ sales and the cobimetinib collaboration. A 2014 restructuring reduced the workforce to approximately 80 full-time employees. For investors, the central issues are the company's need for additional capital, its dependence on the success of cabozantinib in its remaining phase 3 trials and on Genentech's cobimetinib launch, and the near-term Deerfield Notes maturity, which the company plans to extend to July 2018 by exercising an option that must be exercised before March 31, 2015.
- 2013Feb 20, 2014
Exelixis Annual Report, Year Ended Dec 31, 2013
Exelixis, Inc. is a biotechnology company developing small molecule cancer therapies. Its most advanced asset, COMETRIQ (cabozantinib), was approved by the FDA on November 29, 2012 for progressive, metastatic medullary thyroid cancer and became commercially available in late January 2013. In December 2013 the CHMP issued a positive opinion on the EU marketing authorization application, which the European Commission will review. The company reported a 2013 net loss of $244.8 million, an accumulated deficit of $1.5 billion, total revenues of $31.3 million (including $15.0 million of net product revenues from COMETRIQ), and cash and investments of $415.9 million at December 31, 2013. It states it can fund operations for at least 12 months after the end of 2013, but its future capital requirements are substantial and it may need to raise additional capital earlier than expected. The company's debt load is significant: total consolidated indebtedness through maturity was $483.6 million, including $287.5 million of 4.25% convertible notes due 2019, $114.0 million of Deerfield secured convertible notes, and $82.1 million under a Silicon Valley Bank loan. In January 2014 Exelixis amended the Deerfield note purchase agreement to give it an option to extend those notes to July 2018 and issued 1,000,000 warrants at $9.70 per share. It also sold 10.0 million shares at $8.00 per share in January 2014, raising about $75.6 million net. Management expects top-line data from several phase 3 pivotal trials of cabozantinib and cobimetinib in 2014, including COMET-1 and COMET-2 in prostate cancer, the overall survival analysis of the EXAM trial in MTC, and the cobimetinib/vemurafenib melanoma trial. For investors, the key issues are the limited early commercial uptake of COMETRIQ, which the company says addresses an estimated 500 to 700 eligible U.S. patients per year, dependence on the outcome of 2014 pivotal trial readouts, and reliance on external financing and debt covenants. Revenue fell 34% in 2013 as collaboration revenue from Bristol-Myers Squibb was fully recognized, and the company's history of losses is expected to continue.
- 2012Feb 21, 2013
Exelixis Annual Report, Year Ended Dec 28, 2012
Exelixis, Inc. reported a net loss of $147.6 million for 2012 and an accumulated deficit of $1.3 billion, with total revenues of $47.4 million, down from $289.6 million in 2011. The decline reflects 2011 revenue accelerations tied to the terminated Bristol-Myers Squibb 2008 agreement ($99.1 million) and the terminated Sanofi collaboration ($53.1 million), with no comparable license revenue in 2012. Research and development expenses were $128.9 million and general and administrative expenses were $31.8 million for the year. The company's central event was FDA approval of COMETRIQ (cabozantinib) on November 29, 2012 for progressive, metastatic medullary thyroid cancer, with commercial launch in January 2013 at a wholesale acquisition cost of $9,900 for a 28-day supply. The filing estimates 500 to 700 first and second line metastatic MTC patients in the United States each year who will be eligible, so the company expects only limited near-term product revenue. Development continues in metastatic castration-resistant prostate cancer (COMET-1 and COMET-2, top-line results expected in 2014), with phase 3 trials in hepatocellular and renal cell cancer planned for 2013. Balance sheet capital rose sharply in 2012. Cash and investments were $634.0 million at December 31, 2012, supported by $287.5 million of 4.25% convertible notes due 2019 and a February and August 2012 equity offerings. Total debt was $335.7 million, and the company states it expects its resources to fund operations for at least 12 months following the end of 2012. Its loan and security agreement with Silicon Valley Bank requires deposit balances at 100% to 107% of outstanding principal, and the Deerfield Notes carry mandatory prepayments in 2014 and 2015.
- 2011Feb 22, 2012
Exelixis Annual Report, Year Ended Dec 30, 2011
Exelixis, Inc. reported net income of $75.7 million for fiscal 2011, compared with a net loss of $92.3 million in 2010, driven mainly by accelerated license revenue from the early termination of its Bristol-Myers Squibb collaboration on XL281 (effective October 8, 2011) and the wind-down of its Sanofi PI3K discovery collaboration (terminated December 22, 2011). Total revenues rose to $289.6 million from $185.0 million, with license revenues of $245.5 million. The company stated it expects further net losses and negative operating cash flow for the foreseeable future, and that cash used in operations was $159.2 million in 2011. Management attributes the company's future to cabozantinib (XL184), its sole focus, which is in a Phase 3 trial for medullary thyroid cancer (EXAM trial met its primary endpoint, with progression-free survival of 11.2 months versus 4.0 months on placebo) and a rolling NDA was initiated in December 2011, with completion expected in the first half of 2012. Two Phase 3 prostate cancer trials are planned or underway (COMET-2 initiated December 2011; COMET-1 expected in the first half of 2012). The balance sheet at December 31, 2011 showed $283.7 million in cash, marketable securities and long-term investments, including about $85.3 million on deposit as collateral for a Silicon Valley Bank loan. Debt totaled $181.5 million, including $91.4 million of Deerfield secured convertible notes and an $80.0 million Silicon Valley Bank term loan. In February 2012, the company raised approximately $65 million in net proceeds from a public offering, and it states that current resources plus expected collaborator funding and offering proceeds will sustain operations for at least 12 months. An accumulated deficit of $1.1 billion remains, and stockholders' equity was $90.6 million. Key risks include the FDA's refusal to reach a Special Protocol Assessment agreement on the COMET-2 design, dependence on cabozantinib's success, reliance on a small number of collaborators (Bristol-Myers Squibb 59% and Sanofi 39% of 2011 revenues), and covenants in the Deerfield and Silicon Valley Bank agreements that require minimum cash balances.
- 2010Feb 22, 2011
Exelixis Annual Report, Year Ended Dec 31, 2010
Exelixis, Inc. (Nasdaq: EXEL) is a biotechnology company focused exclusively on developing cabozantinib (XL184), its most advanced solely-owned product candidate, for cancer. The company reports that its current clinical program for cabozantinib focuses on metastatic castration-resistant prostate cancer and ovarian cancer, and that a global phase 3 registration trial in medullary thyroid cancer is ongoing, with top-line results expected in the first half of 2011 and a possible NDA submission in the second half of 2011. In December 2010 the company cut its workforce by 143 employees, and it reports 2010 total revenues of $185.0 million, a net loss attributable to Exelixis of $92.3 million, and an accumulated deficit of $1,182.1 million. Financially, the company ended 2010 with $256.4 million in cash, cash equivalents, marketable securities and long-term investments, which includes $96.9 million required to be held on deposit with Silicon Valley Bank under loan covenants. Management states this is expected to fund operations for at least 12 months after the filing date. Total debt was $208.5 million at year-end, including a $124.0 million face amount secured convertible note sold to Deerfield for $80.0 million and an $80.0 million Silicon Valley Bank term loan. The GlaxoSmithKline loan balance of $35.9 million is due October 27, 2011. The filing also discloses covenants requiring specified cash balances and working capital, and it warns that the company will need additional capital. Revenue is concentrated in collaborators: Bristol-Myers Squibb accounted for 50% of 2010 revenues and sanofi-aventis for 42%. Research and development expenses fell to $210.7 million in 2010 from $234.7 million in 2009, while the company's cabozantinib development is the main source of expected future spending.
- 2010Mar 10, 2010
Exelixis Annual Report, Year Ended Jan 1, 2010
Exelixis, Inc. (Nasdaq: EXEL) reported a net loss attributable to Exelixis of $135.2 million for the fiscal year ended January 1, 2010, compared with $162.9 million in 2008, while total revenues rose to $151.8 million from $117.9 million. The increase was driven mainly by the May 2009 sanofi-aventis license and collaboration on XL147 and XL765 and continued recognition of the December 2008 Bristol-Myers Squibb collaboration on XL184 and XL281. Management states that cash and short-term and long-term marketable securities totaled $221.0 million at December 31, 2009, and that these resources, together with expected collaborator funding, will sustain operations for at least 12 months after the filing date. The company expects its 2010 net loss to increase over 2009 and anticipates negative operating cash flow for the foreseeable future. On March 8, 2010, Exelixis implemented a restructuring that reduced its workforce by approximately 40%, or 270 employees, shifting resources toward its lead clinical compounds XL184, XL147 and XL765. The company expects a restructuring charge of approximately $15 million in the first quarter of 2010, with additional facility-related and other charges to follow, and the company is still assessing whether to vacate or sublease facilities. Principal risks highlighted include the $85.0 million GlaxoSmithKline loan (of which $70.8 million was outstanding at year-end, with the second and third installments due in October 2010 and 2011), financial covenants tied to working capital and cash and investments, and a Bristol-Myers Squibb co-development provision that could terminate certain rights if cash reserves fall below $80.0 million. The accumulated deficit stood at $1,089.7 million and total stockholders' deficit at $163.7 million as of year-end 2009. The company's strategy centers on XL184, a MET, VEGFR2 and RET inhibit in a global phase 3 registration trial for medullary thyroid cancer, with a possible NDA submission in the second half of 2011, and on the PI3K inhibitors XL147 and XL765, which sanofi-aventis now funds.
- 2009Mar 10, 2009
Exelixis Annual Report, Year Ended Jan 2, 2009
Exelixis, Inc. reported a net loss of $162.9 million for 2008 (fiscal year ended January 2, 2009, referred to as calendar 2008), compared with $86.4 million in 2007, and an accumulated deficit of $954.5 million. Total revenues rose to $117.9 million from $113.5 million, while research and development expenses increased to $257.4 million. Management expects losses in 2009 to increase over 2008 and anticipates negative operating cash flow for the foreseeable future. Stockholders' equity was a deficit of $57.0 million at December 31, 2008, down from equity of $72.1 million a year earlier. The company's most significant development in the period was a worldwide collaboration with Bristol-Myers Squibb, entered into in December 2008, covering XL184 (its most advanced clinical asset, in Phase 3 for medullary thyroid cancer) and XL281. Bristol-Myers Squibb paid an upfront cash payment of $195.0 million and is required to pay an additional $45.0 million in 2009. Exelixis will co-develop XL184, funding 35% of development costs with Bristol-Myers Squibb funding 65%, after an initial $100.0 million of combined costs borne by Exelixis, and will share 50% of U.S. commercial profits and losses. Management stated that it expects to fund operations for at least 12 months following the filing date and aims to operate independently of the capital markets for a substantial period. Liquidity is tight relative to obligations. Cash, equivalents, marketable securities and other restricted or collateralized investments totaled $284.2 million at December 31, 2008. The company owes $102.2 million in principal and accrued interest on a GlaxoSmithKline loan, with the first installment of $28.1 million principal plus interest due in October 2009. The filing describes covenants under the GSK loan and the Deerfield facility (a $150.0 million loan facility, undrawn at year-end) and states that a cash-reserve threshold of $80.0 million tied to the Bristol-Myers Squibb agreement could terminate co-development and co-promotion rights for XL184 if not restored within 90 days.
- 2007Feb 25, 2008
Exelixis Annual Report, Year Ended Dec 28, 2007
Exelixis, Inc. (filed under the name Exelixis, Inc.) reported a 2007 net loss of $86.4 million, compared with $101.5 million in 2006, on total revenues of $113.5 million, up from $98.7 million. Research and development expenses rose to $225.4 million from $185.5 million, and general and administrative expenses to $44.9 million from $39.1 million. The improvement in net loss was driven largely by non-recurring gains of $18.8 million on the sale of its plant trait business to Dow/Agrigenetics and $18.1 million on the sale of 80.1% of its German subsidiary, Artemis Pharmaceuticals GmbH. Management expects losses in 2008 to increase relative to 2007 and expects negative operating cash flow for the foreseeable future. At December 31, 2007, the company had $299.5 million in cash, cash equivalents and marketable securities, including $30.9 million held by Symphony Evolution, Inc. (SEI) and $7.2 million of restricted cash and investments. Management states these resources will fund operations for at least 12 months following the filing date. Stockholders' equity was $72.1 million, and the accumulated deficit was $791.7 million. The company's GlaxoSmithKline loan covenants require working capital of at least $25.0 million and cash and investments of at least $50.0 million; the filing reports $150.9 million and $292.3 million respectively at year-end. The pipeline is concentrated in oncology, with eleven clinical-stage cancer compounds, led by XL647 (Phase 2, out-licensed to SEI), XL880 (Phase 2, option exercised by GlaxoSmithKline in December 2007) and XL820 (Phase 2). The filing highlights that GlaxoSmithKline declined to exercise its option on XL647 and XL784, and that XL999 was discontinued after cardiac adverse events. Revenue is almost entirely collaboration-based, with Bristol-Myers Squibb (35%), GlaxoSmithKline (24%), Genentech (16%) and Daiichi-Sankyo (10%) accounting for the largest shares in 2007.
- 2006Feb 27, 2007
Exelixis Annual Report, Year Ended Dec 29, 2006
Exelixis, Inc. reported a net loss of $101.5 million for the year ended December 2006, compared with $84.4 million in 2005 and $137.2 million in 2004. Total revenues rose to $98.7 million from $76.0 million, with contract revenues of $62.4 million and license revenues of $36.3 million. Research and development expenses increased to $185.5 million, up from $141.1 million, and general and administrative expenses rose to $39.1 million. The accumulated deficit reached $705.3 million, and stockholders' equity was $52.5 million at year-end. Liquidity is the central investor issue. The company held $263.2 million in cash, marketable securities, investments held by Symphony Evolution, Inc. (SEI), and restricted cash and investments at December 31, 2006, and states it expects these resources to fund operations for at least 12 months. The filing warns that future capital needs could require the company to use capital sooner than expected. Its GlaxoSmithKline loan of $95.2 million carries financial covenants requiring working capital of at least $25.0 million and cash and investments of at least $50.0 million. Repurchasing the three SEI-licensed compounds (XL647, XL999 and XL784) could be required if GlaxoSmithKline selects one of them, and the filing notes the purchase price is tied to $80.0 million of invested capital plus 25% per year. Clinical and partnering developments dominate the outlook. Enrollment in the XL999 Phase II program was suspended in November 2006 over cardiovascular adverse events, and the FDA placed the program on partial clinical hold in December 2006. In January 2007, Bristol-Myers Squibb made a $60.0 million upfront payment under a new collaboration, and Genentech's co-development of XL518 included $25.0 million paid in December 2006 and $15.0 million paid in January 2007. The company had 651 full-time employees at year-end 2006.
- 2005Mar 9, 2006
Exelixis Annual Report, Year Ended Dec 31, 2005
Exelixis, Inc. (filed under its then-name, shown in the filing as Exelixis, Inc.) reported a 2005 net loss of $84.4 million, down from $137.2 million in 2004, on total revenues of $76.0 million versus $52.9 million in 2004. Revenue growth was driven largely by a $21.1 million recognition tied to the termination of the Genoptera collaboration with Bayer, and by 2005 milestones from GlaxoSmithKline. Research and development expense was $141.1 million and general and administrative expense was $27.7 million. The accumulated deficit reached $603.8 million, and stockholders' equity fell to $33.5 million from $50.7 million at year-end 2004. The company stated that cash, cash equivalents, marketable securities, investments held by Symphony Evolution, Inc. and restricted cash totaled $210.5 million at December 31, 2005. Management expects these resources, together with committed SEI financing and other expected collaborator funding, to sustain operations for at least the next 12 months. That estimate includes repayment of a $30.0 million convertible note to Protein Design Labs due in May 2006. The GlaxoSmithKline loan agreement carries financial covenants requiring working capital of at least $25.0 million and cash and investments of at least $50.0 million, and outstanding borrowings and accrued interest under it totaled $91.8 million. The pipeline spans eight clinical compounds and six preclinical compounds. XL119 is in a Phase 3 trial for bile duct tumors, now managed by licensee Helsinn, and XL999 is in six Phase 2 trials. Several compounds were out-licensed in 2005 and late 2005, including XL647, XL999 and XL784 to Symphony Evolution, Inc., XL335 to Wyeth and EXEL2255 to Bristol-Myers Squibb. The company stated it is not party to any material legal proceedings.
- 2004Mar 15, 2005
Exelixis Annual Report, Year Ended Dec 31, 2004
Exelixis, Inc., a biotechnology company, reported a net loss of $137.2 million for 2004 on total revenues of $52.9 million, compared with a net loss of $94.8 million on $51.5 million of revenue in 2003. The loss was driven in part by $26.4 million of acquired in-process research and development tied to the October 2004 acquisition of X-Ceptor Therapeutics, and research and development expenses rose to $137.7 million. Cash, cash equivalents, short-term investments and restricted cash and investments stood at $171.2 million at December 31, 2004, and the company states this will fund planned operations for at least the next 15 months. Stockholders' equity fell to $50.7 million from $161.5 million, and the accumulated deficit reached $519.4 million. The filing highlights concentration and funding risk. GlaxoSmithKline, Genoptera and Bristol-Myers Squibb accounted for approximately 30%, 27% and 19% of 2004 revenue. In January 2005 the GlaxoSmithKline collaboration was amended: GlaxoSmithKline selected a modified program focused on 12 internal programs, and Exelixis may receive a new $30.0 million milestone tied to IND filings or Phase 1 completion in 2005. The company also has $85.0 million of convertible loans from GlaxoSmithKline and a $30.0 million convertible note held by PDL, which matures in May 2006, and it must maintain specified working capital and cash covenants. Clinical development is centered on XL119 (becatecarin), in a Phase 3 trial for bile duct tumors that began in June 2004, along with several Phase 1 programs (XL647, XL999) and preclinical programs in metabolic and cardiovascular disease acquired through X-Ceptor. The company reported 517 full-time employees at year end and states that it expects to pursue additional financing within the 15-month window.
- 2003-AFeb 25, 2004
Exelixis Annual Report (Amendment), Year Ended Dec 31, 2003
Exelixis, Inc., a Delaware company headquartered in South South San Francisco, California, filed this Form 10-K/A to amend its annual report for the fiscal year ended December 31, 2003. The amendment was filed solely to add the Amended and Restated Cancer Collaboration Agreement, dated as of December 15, 2003, with Bristol-Myers Squibb Company as Exhibit 10.41, which was inadvertently omitted from the original report filed on February 20, 2004. Except for that exhibit, the filing states that no other information in the original Form 10-K is amended. The filing reports an aggregate market value of common stock held by non-affiliates of $436,723,221, computed as of the last business day of the second fiscal quarter, and 71,295,105 shares of common stock outstanding as of December 31, 2003. It lists no documents incorporated by reference. The amendment's exhibit index covers the company's principal collaboration, financing, and lease arrangements, including agreements with Bristol-Myers Squibb, SmithKlineBeecham, Bayer, Pharmacia & Upjohn, Protein Design Labs, and Dow AgroSciences, as well as loan and lease agreements with Silicon Valley Bank, Comdisco, and GE Capital. Several of these agreements carry confidential treatment for certain portions. The Form 8-K reports listed for the fourth quarter of 2003 cover a $30.0 million additional borrowing under the SmithKlineBeecham Loan and Security Agreement, the third-quarter 2003 financial results press release, and the departure of the company's President, Research and Development and Chief Scientific Officer.
- 2003Feb 20, 2004
Exelixis Annual Report, Year Ended Dec 31, 2003
Exelixis, Inc. (filed under this name; now trading as EXEL on Nasdaq) reported a net loss of $94.8 million for the year ended December 31, 2003, on total revenues of $51.5 million, compared with a net loss of $86.1 million and revenues of $44.3 million in 2002. Research and development expense rose to $127.6 million from $112.0 million, and the accumulated deficit reached $382.1 million. The company states it expects losses to continue and anticipates negative operating cash flow for the foreseeable future. Cash, cash equivalents, short-term investments and restricted cash and investments totaled $241.9 million at December 31, 2003, which management says will support currently planned operations for at least the next two years. The company's pipeline is led by XL119, a rebeccamycin analogue for which it plans to start a Phase 3 trial for bile duct tumors in the second quarter of 2004. XL784, an ADAM-10 metalloprotease inhibitor, is in Phase 1 trials, and IND filings are planned for XL647 (first quarter of 2004), XL999 (second quarter of 2004) and XL844 (early 2005). Revenue depends heavily on collaborators, with three partners accounting for approximately 31%, 28% and 21% of 2003 revenue. Key partners include GlaxoSmithKline, Bristol-Myers Squibb, Bayer and Dow AgroSciences. The filing also details the company's dependence on collaborations, third-party manufacturing, and patent protection, and notes a 2003 restructuring of its research organization that included a reduction in force of 61 research personnel and the closure of its Tübingen, Germany facility. Management also disclosed that its former Chief Scientific Officer left at the end of 2003.
- 2002Mar 7, 2003
Exelixis Annual Report, Year Ended Dec 31, 2002
Exelixis, Inc. (filed under this name; the filing is for fiscal 2002) reports a net loss of $86.1 million for the year ended December 31, 2002, compared to $71.2 million in 2001 and $75.3 million in 2000, with an accumulated deficit of $287.4 million. Total revenues rose to $44.3 million from $41.0 million in 2001, driven mainly by new collaborations with GlaxoSmithKline, Bristol-Myers Squibb and Protein Design Labs. Research and development expenses increased to $112.0 million from $82.7 million, and the company states it expects operating expenses to increase significantly and negative operating cash flow to continue. Cash, cash equivalents, short-term investments and restricted cash totaled $222.0 million at year-end, and the company says this is sufficient for its currently planned operations for at least the next two years. The company's most advanced clinical program is the rebeccamycin analogue (XL 119), in-licensed from Bristol-Myers Squibb, which has completed Phase I testing and is in a Phase II program conducted by the National Cancer Institute. Its lead proprietary compound, XL 784, is in regulatory toxicology studies, with an IND filing expected in 2003. Revenue is concentrated: two collaborators accounted for approximately 39% and 25% of 2002 total revenue. The October 2002 GlaxoSmithKline alliance is a significant event for investors. GSK paid a $30.0 million upfront fee, $10.0 million in annual research funding, purchased 2,000,000 shares at $7.00 per share, and provided a loan facility of up to $85.0 million, of which $25.0 million was borrowed in December 2002. Stockholders' equity declined to $175.9 million from $237.2 million, and long-term obligations rose to $65.4 million.
- 2001Mar 20, 2002
Exelixis Annual Report, Year Ended Dec 31, 2001
Exelixis, Inc. (filed under the name Exelixis, Inc.) reported a 2001 net loss of $71.2 million on total revenues of $41.0 million, up from $24.8 million in 2000. Research and development expenses rose to $82.7 million from $51.7 million, and the company reported an accumulated deficit of $201.2 million at December 31, 2001. Management states the company expects to incur net losses and negative operating cash flow for the foreseeable future, and that its current cash, cash equivalents, short-term investments and collaborator funding will maintain planned operations for at least the next two years. Cash, cash equivalents and short-term investments totaled $227.7 million at year-end. The year's largest strategic event was the acquisition of Genomica Corporation, a bioinformatics company, in a stock-for-stock transaction valued at $110.0 million, completed January 8, 2002. Exelixis also acquired Artemis Pharmaceuticals GmbH in May 2001 for approximately $24.2 million, and recorded a $6.7 million in-process R&D charge in connection with it. Revenue depends heavily on collaborations: the filing states Bayer accounted for approximately 32% of 2001 revenues and Pharmacia approximately 31%. The Pharmacia collaboration terminated in February 2002, eliminating roughly $9.0 million in annual research revenue that would otherwise have been payable for two more years. The company's most advanced proprietary program is DEAE Rebeccamycin, an in-licensed cancer compound from Bristol-Myers Squibb that is in Phase II trials conducted by the National Cancer Institute. The filing also notes that Exelixis has no manufacturing capability or prior clinical experience and will need to rely on third parties, and that a shareholder suit related to the Genomica merger is pending in Colorado state court.
- 2000Mar 15, 2001
Exelixis Annual Report, Year Ended Dec 31, 2000
Exelixis, Inc. reported a 2000 net loss of $75.3 million on total revenues of $24.8 million, up from $10.5 million in 1999 and $2.3 million in 1998. The loss was driven largely by a $38.1 million charge for acquired in-process research and development tied to the December 2000 acquisition of Agritope, Inc., which was renamed Exelixis Plant Sciences, and by research and development expenses of $48.5 million and selling, general and administrative expenses of $18.9 million. The company says it is a leader in discovering novel drug targets, particularly for cancer, using comparative genomics and model system genetics, and it relies on collaborations with Bayer, Pharmacia, Bristol-Myers Squibb, Dow AgroSciences and Aventis CropScience for funding. Bayer and Pharmacia accounted for approximately 53% and 36% of 2000 revenues, respectively. As of December 31, 2000, cash, cash equivalents and short-term investments totaled $112.6 million, following the May 2000 initial public offering with net proceeds of approximately $127.5 million. Stockholders' equity rose to $162.7 million from a deficit of $49.6 million a year earlier, and the accumulated deficit reached $130.0 million. Management states that current resources should sustain planned operations for at least the next two years, while also warning that it expects continuing losses and may need additional capital. The filing also highlights significant risks: heavy dependence on a small number of collaborators whose agreements have varying expiration and termination provisions, an early-stage technology platform with no proprietary product commercialization experience, and a stock price that closed at $8.75 on March 12, 2001, compared with a 2000 quarterly high of $49.25.